
Opinion|Videos|March 20, 2025
Practical Insights for Pharmacists on ADC Administration, Patient Experience, and Supportive Care
Panelists discuss how antibody-drug conjugates (ADCs) often show more diverse outcomes in real-world settings compared with clinical trials, with varying efficacy and adverse effect profiles. Key practical considerations for pharmacists include appropriate dosing based on patient factors, managing drug interactions, implementing premedication protocols to minimize adverse reactions, and providing comprehensive supportive care. Careful monitoring and individualized patient management are essential for optimal therapeutic outcomes.
Advertisement
Episodes in this series

Video content above has been prompted by the following:
- In your experience, how do real-world data and patient experiences compare with clinical trial results for approved ADCs?
- What practical considerations should pharmacists be aware of when administering ADCs (eg, dosage, premedication regimens, drug interactions, supportive care)?
Advertisement
Related to this article

October’s oncology coverage highlighted new treatment options in rectal, breast, and prostate cancers, alongside longer-term survival findings and concerns about reduced-frequency immunotherapy.

ESMO 2026 breast cancer updates show ribociclib boosts survival, while immunotherapy and extended endocrine therapy improve end points without longer overall survival.

In an interview with Pharmacy Times, Danielle Roman, PharmD, BCOP, FHOPA, discusses NCCN breast cancer guideline updates involving ESR1 mutation testing, targeted therapies, and pharmacists’ roles in monitoring, patient counseling, and treatment access.
Advertisement
Advertisement
Trending on Pharmacy Times
1
CVS Health to Split Into 2 Public Companies, Separating Retail and Specialty Pharmacy
2
Community Pharmacists Guide Patients New to Glucose Monitoring
3
Is Less More? Comparing Metronidazole Dosing in Confirmed Anaerobic Infections
4
FDA Approves Tildrakizumab for Adults With Psoriatic Arthritis
5


